Patents

US 8828356 B2: Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis

Granted
2014-09-09
Filed
2013-04-04 application 13857052
Type
Utility · 14 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.

Source: PVGPATDIS, file of 2026-04-10 (ipg140909.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
The Progeria Research Foundation 10 patentsUS company or organizationPeabody, MAThe Progeria Research Foundation, Inc. State business registration FUZZY medium confidence: same name (legal endings aside) and state
THE PROGERIA RESEARCH FOUNDATION INC Nonprofit FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
PVGPATDIS, file of 2026-04-10
The United States of America as Represented by the Secretary of the Department of Health and Human Services 225 patentsUS federal governmentWashington, DCPVGPATDIS, file of 2026-04-10
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 761 patentsUS company or organizationChapel Hill, NCThe University of North Carolina at Chapel Hill State business registration EXACT high confidence: identical full name and state
University of North Carolina at Chapel Hill College or university FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Nonprofit FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
PVGPATDIS, file of 2026-04-10
THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2,342 patentsUS company or organizationAnn Arbor, MITHE REGENTS OF THE UNIVERSITY OF MICHIGAN CORP. State business registration FUZZY medium confidence: same name (legal endings aside) and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Leslie B. GordonFoxborough, MA13PVGPATDIS, file of 2026-04-10
Francis S. CollinsRockville, MD12PVGPATDIS, file of 2026-04-10
Thomas Grant GloverYpsilanti, MI9PVGPATDIS, file of 2026-04-10
Michael W. GlynnDarien, CT4PVGPATDIS, file of 2026-04-10
Brian C. CapellPhiladelphia, PA4PVGPATDIS, file of 2026-04-10
Adrienne D. CoxChapel Hill, NC5Person page FUZZY medium confidencePVGPATDIS, file of 2026-04-10
Channing J. DerChapel Hill, NC5PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/4545PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P43/00PVGPATDIS, file of 2026-04-10
C07KPeptidesC07K14/47PVGPATDIS, file of 2026-04-10
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms ; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processesC12Q1/6883PVGPATDIS, file of 2026-04-10
G01NInvestigating or analysing materials by determining their chemical or physical propertiesG01N33/68PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2013-05-13Assignment
Assignment of assignor's interest
CAPELL, BRIAN C. signed 2006-05-24
COLLINS, FRANCIS S. signed 2006-05-24
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ROCKVILLE, MD30402/601ECORSEXC, file of 2026-09-25
2013-05-13Assignment
Assignment of assignor's interest
DER, CHANNING J. signed 2006-03-10
COX, ADRIENNE D. signed 2006-03-15
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CHAPEL HILL, NC30402/585ECORSEXC, file of 2026-09-25
2013-05-13Assignment
Assignment of assignor's interest
GLYNN, MICHAEL W. signed 2006-04-11
GLOVER, THOMAS signed 2006-04-12
THE REGENTS OF THE UNIVERSITY OF MICHIGAN ANN ARBOR, MI30402/565ECORSEXC, file of 2026-09-25
2013-05-13Assignment
Assignment of assignor's interest
GORDON, LESLIE B. signed 2006-03-22PROGERIA RESEARCH FOUNDATION, INC. PEABODY, MA30402/519ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.